Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

A functional cure is said to have been achieved if a biomarker called hepatitis B surface antigen (HBsAg) is cleared from the blood and remains undetectable after stopping all treatment.

Notably, those who received nivolumab exhibited higher rates of hepatitis B surface antigen (HBsAg) loss compared to other groups. This is seen as a significant step forward in targeting HBsAg ...

Use the purifier to isolate the hepatitis B antigen produced by the yeast cells. The vaccine, once administered, will stimulate the immune system to attack the antigen (i.e., the protein coat).

Inside the hepatocytes, HBV produces a surplus of viral antigens, including hepatitis B e antigen (HBeAg) and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the ...

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...

Alliance Global Partners analyst James Molloy lowered the firm’s price target on Barinthus Biotherapeutics (BRNS) to $6 from $7.50 and keeps a ...

Thirty-four HBsAg tests were performed on 34 different patients within 14 days of a dose of Engerix-B® hepatitis B vaccine, with 24 of these occurrences involving patients with chronic renal ...